Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

SAN DIEGO - Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biotech company currently valued at $171 million, has shared promising clinical data from its studies of azenosertib, a small ...

Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate ...

This multifaceted role of centrosomes in both cell cycle regulation and cancer highlights their potential as therapeutic targets in oncology.

How Breast Cancer Cells Survive in Bone Marrow After Remission Dec. 4, 2024 — A new study has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells ...

Short-chain fatty acids (SCFAs) like propionate and butyrate are critical byproducts of dietary fiber digestion. These ...

The field of cancer treatment is witnessing rapid advancements due to progress in proteomics, genomics, and drug discovery. These technologies have ...

Cyclin-dependent kinases (CDKs) are protein kinases involved in critical cellular processes, such as cell cycle or transcription ... when developing CDK inhibitors. Protein names like PFTAIRE ...

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ ...